

## SHORT COMMUNICATION

# THE ASSOCIATION OF VITAMIN D WITH METABOLIC SYNDROME IN ADULTS WITH PREDIABETES

MD. SHAHED-MORSHED<sup>1\*</sup>, TAHNIYAH HAQ<sup>2</sup>, SHAHJADA SELIM<sup>3</sup>, HABIBUL GHANI<sup>1</sup>, IBRAHIM FAISAL<sup>1</sup>, ANIL YADAV<sup>1</sup>, ANIL KUMAR SHAH<sup>1</sup>, MD. FARIDUDDIN<sup>4</sup>

### Abstract

**Background:** Vitamin D may play important role in the pathogenesis of several components of metabolic syndrome (MS). The aim of this study was to observe the association of vitamin D with MS and its components in Bangladeshi adults with prediabetes. **Methods:** This cross-sectional study was done among 117 newly detected nonpregnant adults with prediabetes [age (years): 36.30±9.99; BMI (kg/m<sup>2</sup>): 28.89±4.35, mean±SD; M/F: 23/94] based on American Diabetes Association 2018 criteria. Metabolic syndrome was diagnosed by any three of five criteria: central obesity; elevated blood pressure, fasting blood glucose & triglyceride (TG) and lower HDL cholesterol. Glucose was measured by glucose oxidase, lipid by glycerol phosphate dehydrogenase-peroxidase and vitamin D by high performance liquid chromatography method. Vitamin D <20 ng/ml was considered as deficiency (VDD). **Results:** Among all the variables only TG was significantly higher in patients with VDD than those without VDD (≥20 ng/ml) [163.0 (135.50, 224.50) vs. 143.50 (101.25, 190.0), median (IQR), p=0.048]. There were no significant correlations [p=NS for all] and associations of vitamin D with MS or its components in linear and logistic regression [p=NS for all]. **Conclusions:** Except TG vitamin D has no associations with MS or its components in Bangladeshi adults with prediabetes.

**Key words:** vitamin D, metabolic syndrome, prediabetes, triglyceride

Received: 24.4.2021

Accepted: 28.5.2021

DOI: <https://doi.org/10.3329/bjm.v32i2.53805>

**Citation:** Morshed MS, Haq T, Selim S, Ghani H, Faisal I, Yadav A, Shah AK, Fariduddin M. The Association of Vitamin D with Metabolic Syndrome in Adults with Prediabetes. *Bangladesh J Medicine* 2021; 32: 170-174.

### Introduction:

Metabolic syndrome (MS) and prediabetes are two very common conditions among people with Bangladesh (30% & 10.1% respectively)<sup>1,2</sup>. Both the conditions are important modifiable risk factors for cardiovascular diseases. Recent studies suggest that vitamin D deficiency (VDD) is associated with all the components of metabolic syndrome<sup>3</sup>. Vitamin D may play critical role in insulin resistance, pancreatic  $\beta$ -cell dysfunction, meta-inflammation, lipolysis and indirect effects on renin-angiotensin system. These plausible mechanisms are thought to be linked with VDD induced secondary hyperparathyroidism<sup>4,5</sup>. VDD also plays an important role in progression from prediabetes to full blown diabetes mellitus<sup>6</sup>. However, data are limited for Bangladeshi individuals with prediabetes regarding the association of vitamin D with MS. This study was aimed to see the relationships of vitamin D

level and status with MS and its components among Bangladeshi adults with prediabetes.

### Methods:

This cross-sectional study was done among 117 newly detected and untreated nonpregnant adults with prediabetes [age (years): 36.30±9.99; body mass index (BMI) (kg/m<sup>2</sup>): 28.89±4.35, mean±SD]. Prediabetes was diagnosed according to American Diabetes Association 2018 criteria<sup>7</sup>. Participants who were taking or had received vitamin D or calcium within last 120 days of sample collection; taking any medications that alter vitamin D level; having any disorders affecting vitamin D metabolism and pregnancy or lactation were excluded from the study. Participants were recruited consecutively by purposive sampling technique during the period of July 2018 to September 2019. After taking informed written consent, clinical information [age, sex,

1. Emergency Medical Officer, Kurmitola General Hospital, Dhaka-1207, Bangladesh.
2. Assistant Professor, Department of Endocrinology, BSMMU, Dhaka, Bangladesh
3. Associate Professor, Department of Endocrinology, BSMMU, Dhaka Bangladesh
4. Professor, Department of Endocrinology, BSMMU, Dhaka, Bangladesh

**Address of Correspondence:** Dr. Md. Shahed Morshed, Emergency Medical Officer, Kurmitola General Hospital, Dhaka-1207, Bangladesh. Email: shahedk62@gmail.com. Cell +88 01738-842019

height, weight, waist circumference and blood pressure (BP) were collected in a pretested, semi-structured data sheet. Fasting venous blood was taken from each individual to measure glucose (FBG), lipid profile and vitamin D. Glucose was measured by glucose oxidase, lipid by glycerol phosphate dehydrogenase-peroxidase method and vitamin D by high performance liquid chromatography method. Obesity was defined by BMI  $\geq 25 \text{ kg/m}^2$  and metabolic syndrome was diagnosed by a combination of any three out of five criteria: central obesity (male  $\geq 90 \text{ cm}$ , female  $\geq 80 \text{ cm}$ ), metabolic syndrome BP (MS-BP)  $\geq 130/85 \text{ mm-Hg}$ , metabolic syndrome FBG (MS-FBG)  $\geq 5.6 \text{ mmol/L}$ , metabolic syndrome HDL-C (MS-HDL-C) (male  $< 40 \text{ mg/dl}$ , female  $< 50 \text{ mg/dl}$ ) and metabolic syndrome TG (MS-TG)  $\geq 150 \text{ mg/dl}$ <sup>8,9</sup>. A modified vitamin D status consisting of only vitamin D deficiency ( $< 20 \text{ ng/ml}$ ) and without vitamin D deficiency ( $\geq 20 \text{ ng/ml}$ ) was considered<sup>10</sup>. The study protocol was approved by institutional review board of BSMMU (No. BSMMU/2018/4826).

Data were analyzed by SPSS software version 22.0. Data were expressed in mean  $\pm$  standard deviation (SD) or median (interquartile range, IQR) (TG) and frequency (percentages, %) as appropriate. Comparison between two groups were done by independent-samples t test

or Mann-Whitney U test and among more than two groups by one-way ANOVA or Kruskal Wallis one-way ANOVA test for quantitative variables and Pearson's chi-square/Fisher's exact test for qualitative variables. Correlations of vitamin D with all the quantitative variables were done by Pearson's or Spearman's (TG) correlation test. Linear regression analysis was done with vitamin D level as dependent variable and logistic regression analysis was done with vitamin D status as dependent variable. A two-tailed  $p < 0.05$  was considered as statistically significant.

**Results:**

Table I is showing the characteristics of the study population according to vitamin D status. Age, BMI, WC, systolic & diastolic BP, FBG, TC, LDL-C, HDL-C all were statistically similar between the groups with or without VDD [ $p = \text{NS}$  for all]. Only TG (mg/dl) was significantly higher in VDD group than non-VDD group [163.0 (135.50, 224.50) vs. 143.50 (101.25, 190.0), median (IQR),  $p = 0.048$ ]. There were no significant differences in sex, general obesity and metabolic syndrome categories including its all components' categories between the vitamin D groups [ $p = \text{NS}$  for all].

**Table-I**  
*Characteristics of the study population according to vitamin D status*

Variables	VDD (<20 ng/ml)	Without VDD ( $\geq 20 \text{ ng/ml}$ )	p
No. (%)	53 (45.3)	64 (54.7)	
Age, years	37.49 $\pm$ 9.56	35.31 $\pm$ 10.30	0.242†
Sex			
Male	13 (56.5)	10 (43.5)	0.251Å
Female	40 (42.6)	54 (57.4)	
BMI, $\text{kg/m}^2$	29.05 $\pm$ 4.15	28.75 $\pm$ 4.53	0.710†
Obese (BMI $\geq 25 \text{ kg/m}^2$ )	44 (46.8)	9 (39.1)	0.641Å
Waist circumference, cm			
Male	98.59 $\pm$ 13.85 [13]	89.80 $\pm$ 14.48 [10]	0.154†
Female	99.08 $\pm$ 8.80 [40]	97.78 $\pm$ 10.42 [54]	0.524†
Central obesity (M $\geq 90$ , F $\geq 80$ )	51 (47.2)	2 (22.2)	0.180Å
Systolic BP, mm-Hg	120.51 $\pm$ 15.42	115.83 $\pm$ 14.25	0.091†
Diastolic BP, mm-Hg	81.92 $\pm$ 11.22	79.14 $\pm$ 8.68	0.133†
MS- BP ( $\geq 130/85$ )	26 (54.2)	27 (39.1)	0.132Å
FBG, mmol/L	5.83 $\pm$ 0.58	5.75 $\pm$ 0.65	0.492†
MS-FBG ( $\geq 5.6$ )	37 (44.6)	16 (47.1)	0.840Å
HDL-cholesterol, mg/dl			
Male	35.85 $\pm$ 8.26 [13]	38.70 $\pm$ 6.22 [10]	0.373†
Female	41.78 $\pm$ 9.09 [40]	43.80 $\pm$ 9.72 [54]	0.307†
MS-HDL-C (M $< 40$ , F $< 50$ )	43 (49.4)	10 (33.3)	0.142Å
Triglyceride, mg/dl	163.0 (135.50, 224.50)	143.50 (101.25, 190.0)	0.048*
MS-TG ( $\geq 150 \text{ mg/dl}$ )	30 (50.0)	23 (40.4)	0.354Å
Metabolic syndrome	44 (50.6)	9 (30.0)	0.058Å

Within parentheses are percentages over column total

†Independent-samples T test or \*Mann-Whitney U test was done

ÅPearson's chi-square/Fisher's exact test was done as appropriate

The vitamin D level and VDD status of the study population among groups of MS and its different components are shown in Table 2. None of the associations between vitamin D level or VDD status with MS or its any components were statistically significant (p=NS for all).

Vitamin D had no significant correlation [WC: r=-0.084, p=0.366; SBP: r=-0.025, p=0.786; DBP: r=-0.017, p=0.856; FBG: r=-0.013, p=0.893; TG: r=-0.140, p=0.132; HDL-C: r=0.083, p=0.372] or predictive association by multivariate linear regression with any

components of MS [WC:  $\beta$ =-0.176, p=0.325; SBP:  $\beta$ =0.062, p=0.672; DBP:  $\beta$ =-0.060, p=0.670; FBG:  $\beta$ =0.066, p=0.517; TG:  $\beta$ =0.028, p=0.804; HDL-C:  $\beta$ =0.093, p=0.372]. Similarly, MS and none of components of MS could predict VDD by multivariate binary logistic regression model [odds ratio (95% confidence interval)- MS: 0.538 (0.108, 2.673), p=0.448; central obesity: 1.903 (0.319, 11.368), p=0.480; MS-BP: 1.471 (0.650, 3.330), p=0.355; MS-FBG: 0.666 (0.245, 1.811), p=0.425; MS-TG: :MS-HDL-C: 1.265 (0.403, 3.968), p=0.687].

**Table-II**  
*Vitamin D level and status among different components of metabolic syndrome*

Variables	Categories	Vitamin D, ng/ml mean±SD	p†	VDD, no. (%)*	p*
Waist circumference	Centrally obese (n=108)	20.42±10.59	0.094	51 (47.2)	0.180
	Nonobese (n=9)	26.57±9.12		2 (22.2)	
Blood pressure	MS-BP (n=48)	20.18±10.57	0.546	26 (54.2)	0.132
	Optimal (n=69)	21.39±10.63		27 (39.1)	
Fasting blood glucose	MS-FBG (n=83)	21.24±10.51	0.584	37 (44.6)	0.840
	Normal (n=34)	20.05±10.84		16 (47.1)	
HDL- cholesterol	MS-HDL-C (n=87)	20.34±10.58	0.332	30 (34.5)	0.354
	Less risk (30)	22.52±10.57		23 (76.7)	
Triglyceride	MS-TG (n=60)	20.16±10.17	0.441	43 (71.7)	0.142
	Optimal (n=57)	21.67±11.03		10 (17.5)	
Metabolic syndrome	Present (n=87)	20.13±10.43	0.182	44 (50.6)	0.058
	Absent (n=30)	23.12±10.85		9 (30.0)	
Metabolic syndrome with obesity interaction	MS + Obese (n=76)	19.58±10.69	0.336	39 (51.3)	0.270
	MS – obese (n=11)	23.88±7.83		5 (45.5)	
	– MS+obese (n=18)	22.82±11.38		5 (27.8)	
Number of component of metabolic syndrome	– MS–obese (n=12)	23.58±10.48	0.271	4 (33.3)	0.057
	One (n=12)	26.98±7.69		1 (8.3)	
	Two (n=17)	19.58±11.66		8 (47.1)	
	Three (n=29)	20.64±11.73		13 (44.8)	
	Four (n=42)	19.46±9.80		24 (57.1)	
	Five (n=17)	21.91±10.56		7 (41.2)	

Within parentheses are percentages over row total

†Independent-samples t test or one-way ANOVA test was done

\*Pearson’s chi-square test/Fisher’s exact test was done as appropriate

**Discussion:**

This cross-sectional study included 117 newly detected and untreated nonpregnant adults with prediabetes. Among them 53 (45.3%) had VDD and 87 (74.4%) had MS. Dutta et al. 2013 also found a similar percentages of VDD (43.3%) in patients with prediabetes<sup>11</sup>. However, we found a higher prevalence of MS among adults with prediabetes than other studies. This is most likely the lower cut-off value we used to define WC (Asian) that is lower than those studies<sup>12,13</sup>.

Patients with VDD had higher level of TG than patients without VDD. There were no other significant correlations and predictive associations between vitamin D with MS. Similar findings were also found by a study conducted among prediabetic patients of West Bengal, India<sup>11</sup>. While Tian et al. 2019 found significant associations of vitamin D with all the components of MS in participants with prediabetes, Kwon and Lim, 2016 found association only with HDL-C<sup>12,13</sup>. We did not find association of vitamin D with MS. This is similar to the observation of Kwon and Lim in Korean population and Wieder-Huszla et al. 2019 in women of Poland<sup>12,14</sup>. Vitamin D was not found as an independent predictor of fasting lipids in a British Bangladeshi adults<sup>15</sup>. Therefore, the associations of vitamin D with MS and its components in patients with prediabetes are not consistent. Even the association of vitamin D with the mediator of prediabetes and MS i.e. insulin resistance was also not observed in a previous study among Bangladeshi adults with prediabetes<sup>16</sup>. Although the association between vitamin D with MS was found in cross-sectional studies, it was not found in longitudinal studies<sup>17</sup>. Furthermore, vitamin D supplementation did not improve insulin sensitivity and metabolic parameters in patients with MS<sup>18</sup>. These study findings indicate that the role of vitamin D in mediating the components of MS is minimal. However, our study sample size was small and it was a cross-sectional study. Further longitudinal study can be done with larger sample size to find out the actual relationship between vitamin D with MS in patients with prediabetes.

**Conclusions:**

VDD and MS are common in Bangladeshi adults with prediabetes. Hypertriglyceridemia is associated with VDD but it is not an independent predictor of vitamin D level or VDD. Vitamin D has no other associations with MS and its components in adults with Prediabetes.

**Acknowledgement:**

We are grateful to Department of Biochemistry, BSMMU and Center for Advance Research in Sciences (CARS), Dhaka University for technical support.

**Funding:**

Partial funding by University Research & Development, BSMMU and Beximco Pharmaceuticals Limited are duly acknowledged.

**Conflict of interest:**

None of the authors has any conflict of interest to declare

**Ethical consideration:**

The study was conducted after approval from the ethical review committee. The confidentiality and anonymity of the study participants were maintained.

**References:**

1. Chowdhury MZI, Anik AM, Farhana Z, Bristi PD, Abu Al Mamun BM, Uddin MJ, et al. Prevalence of metabolic syndrome in Bangladesh: A systematic review and meta-analysis of the studies. *BMC Public Health* 2018; 18(1):308. <https://doi.org/10.1186/s12889-018-5209-z>. PMID:29499672 PMCid:PMC5833131.
2. Akhtar S, Nasir JA, Sarwar A, Nasr N, Javed A, Majeed R, et al. Prevalence of diabetes and pre-diabetes in Bangladesh: a systematic review and meta-analysis. *BMJ Open* 2020; 10(9):e036086. <https://doi.org/10.1136/bmjopen-2019-036086>. PMID:32907898 MCid:PMC 7482481.
3. Awad AB, Alappat L, Valerio M. Vitamin D and metabolic syndrome risk factors: Evidence and mechanisms. *Crit Rev Food Sci Nutr* 2012; 52(2):103-12. PMID: 22059957. <https://doi.org/10.1080/10408391003785458> PMID: 22059957.
4. Nakashima A, Yokoyama K, Yokoo T, Urashima M. Role of vitamin D in diabetes mellitus and chronic kidney disease. *World J Diabetes* 2016;7(5):89. <https://doi.org/10.4239/wjd.v7.i5.89>. PMID:26981182 PMCid:PMC4781904
5. Miñambres I, Sanchez-Quesada JL, Pérez A. The association between hypovitaminosis D and metabolic syndrome: Current understanding. *Clinical Lipidology* 2015;10(6):513-24. <https://doi.org/10.2217/clp.15.38>
6. Yu L, Zhai Y, Shen S, Wane D. Association between Vitamin D and prediabetes: A PRISMA-compliant meta-analysis. *Medicine (Baltimore)* 2020; 99(8):e19034. <https://doi.org/10.1097/MD.00000000000019034>. PMID:32080077 PMCid: PMC7034644
7. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in Diabetes-2018. *Diabetes Care* 2018;41(Suppl 1):S13-27. <https://doi.org/10.2337/dc18-S002>. PMID:29222373
8. World Health Organization. Regional Office for the Western Pacific. Redefining obesity and its treatment. Sydney : Health Communications Australia:55p. <https://apps.who.int/iris/handle/10665/206936>.
9. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the

- international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International. *Circulation* 2009; 120(16):1640-5. <https://doi.org/10.1161/CIRCULATIONAHA.109.192644>. PMID:19805654
10. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96(7):1911-30. <https://doi.org/10.1210/jc.2011-0385>. PMID:21646368
  11. Dutta D, Maisnam I, Shrivastava A, Sinha A, Ghosh S, Mukhopadhyay P, et al. Serum vitamin-D predicts insulin resistance in individuals with prediabetes. *Indian J Med Res* 2013;138(6):853-60. PMID: PMC3978972.
  12. Kwon HN, Lim HN. Relationship between serum vitamin D status and metabolic risk factors among korean adults with prediabetes. *PLoS One* 2016; 11(10): e0165324. <https://doi.org/10.1371/journal.pone.0165324>. PMID: 27783655 PMID:PMC5082612
  13. Tian LQ, Shi WQ, Zhou Y, Zhang YW, Zhang ML. The association of serum vitamin d deficiency and metabolic risk factors in chinese adults with prediabetes: A cross-sectional study. *J Nutr Sci Vitaminol (Tokyo)* 2019;65(3):211-8. <https://doi.org/10.3177/jnsv.65.211> PMID:31257260
  14. Wieder-Huszla S, Jurczak A, Szkup M, Barczak K, Do<sup>3</sup>ęowska B, Schneider-Matyka D, et al. Relationships between vitamin D 3 and metabolic syndrome. *Int J Environ Res Public Health* 2019;16(2):175. <https://doi.org/10.3390/ijerph16020175>. PMID:30634516 PMID:PMC6352038
  15. John WG, Noonan K, Mannan N, Boucher BJ. Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. *Am J Clin Nutr* 2005;82(3):517-22. <https://doi.org/10.1093/ajcn.82.3.517> PMID: 16155262
  16. Morshed MS, Haq T, Selim S, Khan MA, Mustari M, Rajib MH, et al. The Association between Vitamin D and Insulin Resistance among Adults with Prediabetes. *EC Diab Metab Res* 2020;4(4):18-27. URL: <https://www.echronicon.com/ecdmr/pdf/ECDMR-04-00080.pdf>.
  17. Ju SY, Jeong HS, Kim DH. Blood vitamin D status and metabolic syndrome in the general adult population: A dose-response meta-analysis. *J Clin Endocrinol Metab* 2014;99(3):1053-63. <https://doi.org/10.1210/jc.2013-3577> PMID:24423309
  18. Wongwiwatthananut S, Sansanayudh N, Phetkrajaysang N, Krittiyanunt S. Effects of vitamin D2 supplementation on insulin sensitivity and metabolic parameters in metabolic syndrome patients. *J Endocrinol Invest* 2013;36(8):558-63. <https://doi.org/10.3275/8817>. PMID: 23385553.